Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Aoife BrennanPresident and CEO | Climb BioCLYM | Open-market sale10b5-1 plan | 06/29 | 06/30 | 30,902 sh | $13.17 | $406,979.34 | −26.0% |
Climb BioCLYM | Open-market sale10b5-1 plan | 02/25–02/26 | 02/27 | 50,000 sh2 trades | $7.00avg. | $350,163.13 | −24.4% | |
Climb BioCLYM | Open-market sale10b5-1 plan | 02/12–02/13 | 02/17 | 100,000 sh2 trades | $5.29avg. | $528,800 | −32.8% | |
RA Capital Healthcare FundDirector | Climb BioCLYM | Open-market buy | 01/05 | 01/07 | 7,111 sh | $3.50 | $24,888.5 | +0.2% |
Ra Capital ManagementDirector | Climb BioCLYM | Open-market buy | 01/05 | 01/07 | 7,111 sh | $3.50 | $24,888.5 | +0.2% |
Peter KolchinskyDirector | Climb BioCLYM | Open-market buy | 01/05 | 01/07 | 7,111 sh | $3.50 | $24,888.5 | +0.2% |
Rajeev M. ShahDirector | Climb BioCLYM | Open-market buy | 01/05 | 01/07 | 7,111 sh | $3.50 | $24,888.5 | +0.2% |
RA Capital Nexus FundDirector | Climb BioCLYM | Open-market buy | 01/05 | 01/07 | 7,111 sh | $3.50 | $24,888.5 | +0.2% |
RA Capital Nexus Fund IIDirector | Climb BioCLYM | Open-market buy | 01/05 | 01/07 | 7,111 sh | $3.50 | $24,888.5 | +0.2% |
RA Capital Nexus Fund IIIDirector | Climb BioCLYM | Open-market buy | 01/05 | 01/07 | 7,111 sh | $3.50 | $24,888.5 | +0.2% |
Climb BioCLYM | Open-market buy | 25/12/11–25/12/12 | 25/12/15 | 314,561 sh2 trades | $2.40avg. | $754,737.14 | +10.2% | |
Director | Climb BioCLYM | Open-market buy | 25/12/11–25/12/12 | 25/12/15 | 314,561 sh2 trades | $2.40avg. | $754,737.14 | +10.2% |
Climb BioCLYM | Open-market buy | 25/12/11–25/12/12 | 25/12/15 | 314,561 sh2 trades | $2.40avg. | $754,737.14 | +10.2% | |
Climb BioCLYM | Open-market buy | 25/12/11–25/12/12 | 25/12/15 | 314,561 sh2 trades | $2.40avg. | $754,737.14 | +10.2% | |
Climb BioCLYM | Open-market buy | 25/12/11–25/12/12 | 25/12/15 | 314,561 sh2 trades | $2.40avg. | $754,737.14 | +10.2% | |
Climb BioCLYM | Open-market buy | 25/12/11–25/12/12 | 25/12/15 | 314,561 sh2 trades | $2.40avg. | $754,737.14 | +10.2% | |
Climb BioCLYM | Open-market buy | 25/12/11–25/12/12 | 25/12/15 | 314,561 sh2 trades | $2.40avg. | $754,737.14 | +10.2% | |
Aoife BrennanPresident and CEO | Climb BioCLYM | Open-market sale10b5-1 plan | 25/06/30 | 25/07/01 | 20,618 sh | $1.22 | $25,153.96 | −30.0% |
Emily PimblettSVP, Finance & CAO | Climb BioCLYM | Open-market sale10b5-1 plan | 25/06/20 | 25/06/20 | 1,242 sh | $1.24 | $1,540.08 | −6.2% |
Emily PimblettSVP, Finance & CAO | Climb BioCLYM | Open-market sale10b5-1 plan | 25/03/20 | 25/03/20 | 1,199 sh | $1.31 | $1,570.69 | −7.3% |
